SUMMARY It is important to understand the full implications of introducing a new screening and treatment programme into the National Health Service. In this paper, we calculate, for mild hypertension, the cost of community-based screening and the cost of case-finding in general practice. We show that case-finding in general practice is both less expensive and more efficient. We calculate the cost of running a programme in general practice for five years and divide that cost by an estimate of the number of deaths that might be prevented as a result of introducing such a programme. This calculation gives a minimum cost for extending a life by the programme.
At present the Medical Research Council is engaged in a randomised controlled trial to determine the effectiveness of treatment for mild hypertension (diastolic-Phase V-blood pressure of 90-109 mmHg) in adults aged 35 to 64 years (Medical Research Council, 1977) . Mild hypertension is generally symptomless (Beevers et al., 1975) . If the results of the trial show that treatment should be offered to this group, health examinations of the population will therefore be needed to identify cases for treatment (Hawthorne et al., 1974) . Because such a programme would involve large numbers of people and a substantial cost to the National Health Service, it is important to consider its full implications. A comprehensive analysis has already been completed in the United States (Weinstein and Stason, 1976) but sufficient data to carry out a comparable study in the United Kingdon are not at present available. In this paper, we consider the costs of screening for mild hypertension and estimate some of the benefits.
Method
Two methods of identifying cases of mild hypertension are considered. Firstly, we calculate costs for community-based screening, in which a special clinic is established to screen the population of a particular area. Secondly, we consider case-finding by general practitioners, in which GPs take the opportunity to measure blood pressure whenever people attend the practice centre. Costs are calculated for a population of 100 000 men in which all men aged 35 to 64 years would be at risk, and for a population of 100000 women in which all women aged 35 to 64 years would be at risk. All costs are adjusted to 1976 prices. A technical appendix explaining costing in more detail is available from the authors.
The costs of community-based screening are calculated as follows. About 75 % of the population are likely to attend a special screening clinic (Hawthorne et al., 1976) . Of these, between 5 6% and 40 2%, the proportion depending on age and sex (Paisley Midspan Survey), will register an initial diastolic blood pressure reading of 90 mmHg or higher. These people will be asked to make two visits to their GP for further readings. About 40% of those who initially register a high reading will have this confirmed after three sets of readings (Tudor Hart, 1970; Pedersen and Nielsen, 1975 These mortality statistics are based on only one blood pressure reading, so about 60% of those in the high blood pressure groups could be expected to have normal blood pressure after two more sets ofreadings (Tudor Hart, 1970; Pedersen and Nielsen, 1975) . Thus, these mortality rates probably underestimate the true excess mortality in the higher blood pressure groups. On the other hand, we assume in the calculation that treatment of high blood pressure reduces the mortality rate to that of the group with initial blood pressure less than 90 mmHg, an assumption unlikely to be realised.
Applying the differences in mortality rates between high blood pressure and normal blood pressure groups to the numbers on treatment each year gives the number of deaths prevented by treatment. This is discounted at 10% for future years, as for costs. Dividing the cost of the programme by the number of deaths prevented gives a cost per death prevented, or a minimum cost for extending a life by the programme. If we decide to run the programme, we are valuing extending a person's life at at least the amount stated; if we choose not to run the programme, we are valuing extending a person's life at less than the amount stated.
Results
The cost for each new hypertensive person detected is shown in Table 2 for community-based screening and in Table 3 for general practice case-finding. It can be seen that, in most cases, the costs for a community-based screening programme are more than double the costs for general practice casefinding. Because of this, the costs of identifying new patients are based on case-finding by general practitioners in the remainder of the study.
The total cost of running a five-year general practice programme for a population of 100000 men would be £294 000, of which £178 000 would be incurred by the health service. The total cost for women would be £198 000, including £130 000 incurred by the health service. The minimum cost of extending a life implied by choosing to run the programme is shown in Table 4 . 
Discussion
Community-based screening programmes are expensive because they involve the identification of the target population and the establishment of special screening clinics. However, such programmes also provide an opportunity to screen for a number of other conditions. Attendance rates at clinics are usually about 75 % (Hawthorne et al., 1976) and it is unlikely that higher rates could be achieved without a substantial increase in cost. On the other hand, 60% of men and 67% of women aged 45 to 64 years consult their general practitioner in a year (Office of Population Censuses and Surveys, 1974) and in Scotland 85% of men and women aged 40 to 49 years consult their general practitioner at least once in three years (Hawthorne, 1977) . Thus in five years there is an opportunity to screen at least 85% and possibly more of the population. A general practitioner with 2500 patients might expect to screen 338 people in a year (six or seven a week). Using the prevalence rate described, he might eventually expect to be treating a total of 194 patients.
During the first five years of the programme a new section of the population is being screened each year, so a large number of new hypertensive patients is being detected each year. Costs for the second five-year span are perhaps more representative of those likely to arise once the programme is running. Case-finding costs to the health service would rise to £9 89 for men and £12 55 for women. Total case-finding costs would rise to £26 04 for men and £27 79 for women.
It is disappointing to realise how little is known of the prevalence of a condition as apparently common as hypertension. The assumptions made in this study lead to the prevalence rates shown in Table 5 . There is, however, no firm basis for these values. In consequence, calculations have been repeated for two different situations: one in which the proportion of people having an intial high blood pressure reading confirmed is 30% (instead of 40 %), and one in which it is 50%. These lead to prevalence in men of 9 *4 % and 15 * 6 % respectively. The lapse rate, assumed to be 10%, may also vary, depending on the patients' perceptions of the consequences of stopping treatment. Calculations were made for lapse rates of 5 % and 20 % per year. The results for the implicit costs of extending a life for the different situations are shown in (Mooney, 1977) . The implicit value method used here is incomplete, if there is also a substantial saving in morbidity. Weinstein and Stason (1976) overcome this problem by using 'quality-adjusted life years' as a measure of the benefit of treatment, and a similar concept could be employed in a British study.
The MRC trial should provide information on prevalence, lapse rates, and side effects of drugs, as well as on morbidity and mortality prevented by treatment. A more detailed and accurate analysis will then be possible. In particular, the analysis should show which groups in the community are most likely to benefit, and thus where selective screening or case-finding should begin.
Although an analysis of costs and benefits does not provide a definite answer to whether a programme should be introduced or not, it aims to help the decision-maker by removing uncertainty from as many areas as possible, thus contributing to the process of more rational policy-making in the National Health Service.
